STEP HFpEF study
STEP HFpEF (Semaglutide Treatment Effect in People with Obesity, Heart Failure with Preserved Ejection Fraction)
This study will investigate how well a new drug called semaglutide works at helping people lose weight and reduce symptoms of heart failure.
Participation in the study will last for 59 weeks.
It is being carried out in Greater Manchester by a team cased at the Manchester Heart Centre, part of Manchester University NHS Foundation Trust.
- Aged 18+
- BMI (body mass index) over 30
- Diagnosed with heart failure
- With or without type 2 diabetes*
* People with diabetes should not currently take a GLP-1 analogue (non-insulin injectable medications, eg Byetta, Victoza etc)
Taking part will involve:
- Taking a once-a-week injection of semaglutide to help improve control of blood glucose*
- 12 clinic appointments which will include a range of tests (eg blood samples, electrocardiogram/heart test, eye check etc) as well as questions about lifestyle and medical history
- Keeping a study diary
Reasonable travel expenses reimbursed for clinic visits
* Participants will be randomly selected to receive either the treatment drug or a placebo. All participants would continue to take any prescribed medications.